Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
$100m buys an option over another third-gen drug, but Scemblix casts a long shadow.
Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.
The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.
The company defends its cancer strategy, and says it's not a me-too developer.
As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.
